|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GOT2 |
Gene summary for GOT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GOT2 | Gene ID | 2806 |
| Gene name | glutamic-oxaloacetic transaminase 2 | |
| Gene Alias | DEE82 | |
| Cytomap | 16q21 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P00505 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2806 | GOT2 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.61e-05 | 3.08e-01 | -0.1954 |
| 2806 | GOT2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.45e-08 | 5.73e-01 | -0.059 |
| 2806 | GOT2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.28e-07 | 6.51e-01 | 0.281 |
| 2806 | GOT2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.74e-11 | 5.42e-01 | 0.3859 |
| 2806 | GOT2 | A015-C-203 | Human | Colorectum | FAP | 4.51e-08 | -1.69e-01 | -0.1294 |
| 2806 | GOT2 | A002-C-201 | Human | Colorectum | FAP | 2.29e-02 | -1.41e-01 | 0.0324 |
| 2806 | GOT2 | A001-C-108 | Human | Colorectum | FAP | 6.70e-05 | -1.59e-01 | -0.0272 |
| 2806 | GOT2 | A002-C-205 | Human | Colorectum | FAP | 6.99e-05 | -2.05e-01 | -0.1236 |
| 2806 | GOT2 | A015-C-006 | Human | Colorectum | FAP | 6.81e-03 | -1.96e-01 | -0.0994 |
| 2806 | GOT2 | A002-C-114 | Human | Colorectum | FAP | 3.04e-03 | -1.85e-01 | -0.1561 |
| 2806 | GOT2 | A015-C-104 | Human | Colorectum | FAP | 1.20e-10 | -2.24e-01 | -0.1899 |
| 2806 | GOT2 | A002-C-016 | Human | Colorectum | FAP | 2.21e-03 | -1.76e-01 | 0.0521 |
| 2806 | GOT2 | A001-C-203 | Human | Colorectum | FAP | 1.33e-02 | -1.76e-01 | -0.0481 |
| 2806 | GOT2 | A002-C-116 | Human | Colorectum | FAP | 6.63e-07 | -1.79e-01 | -0.0452 |
| 2806 | GOT2 | A018-E-020 | Human | Colorectum | FAP | 6.69e-05 | -2.21e-01 | -0.2034 |
| 2806 | GOT2 | F034 | Human | Colorectum | FAP | 4.49e-04 | -1.84e-01 | -0.0665 |
| 2806 | GOT2 | F072B | Human | Colorectum | FAP | 1.71e-06 | -1.99e-01 | 0.257 |
| 2806 | GOT2 | LZE2T | Human | Esophagus | ESCC | 2.42e-04 | 9.84e-01 | 0.082 |
| 2806 | GOT2 | LZE4T | Human | Esophagus | ESCC | 4.31e-20 | 5.93e-01 | 0.0811 |
| 2806 | GOT2 | LZE7T | Human | Esophagus | ESCC | 1.44e-10 | 9.13e-01 | 0.0667 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
| GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
| GO:0044282 | Colorectum | AD | small molecule catabolic process | 118/3918 | 376/18723 | 1.05e-06 | 3.55e-05 | 118 |
| GO:0030879 | Colorectum | AD | mammary gland development | 53/3918 | 137/18723 | 1.46e-06 | 4.58e-05 | 53 |
| GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
| GO:0050878 | Colorectum | AD | regulation of body fluid levels | 108/3918 | 379/18723 | 2.54e-04 | 3.20e-03 | 108 |
| GO:0016054 | Colorectum | AD | organic acid catabolic process | 73/3918 | 240/18723 | 3.20e-04 | 3.81e-03 | 73 |
| GO:0006575 | Colorectum | AD | cellular modified amino acid metabolic process | 59/3918 | 188/18723 | 4.80e-04 | 5.27e-03 | 59 |
| GO:0043648 | Colorectum | AD | dicarboxylic acid metabolic process | 34/3918 | 96/18723 | 7.22e-04 | 7.28e-03 | 34 |
| GO:0007589 | Colorectum | AD | body fluid secretion | 33/3918 | 93/18723 | 8.26e-04 | 8.13e-03 | 33 |
| GO:0046395 | Colorectum | AD | carboxylic acid catabolic process | 70/3918 | 236/18723 | 9.06e-04 | 8.71e-03 | 70 |
| GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:0097305 | Colorectum | AD | response to alcohol | 71/3918 | 253/18723 | 4.01e-03 | 2.80e-02 | 71 |
| GO:0007595 | Colorectum | AD | lactation | 18/3918 | 47/18723 | 4.81e-03 | 3.25e-02 | 18 |
| GO:00487322 | Colorectum | MSS | gland development | 143/3467 | 436/18723 | 3.85e-13 | 8.01e-11 | 143 |
| GO:00308792 | Colorectum | MSS | mammary gland development | 51/3467 | 137/18723 | 1.88e-07 | 8.26e-06 | 51 |
| GO:00508782 | Colorectum | MSS | regulation of body fluid levels | 99/3467 | 379/18723 | 1.40e-04 | 2.07e-03 | 99 |
| GO:00065751 | Colorectum | MSS | cellular modified amino acid metabolic process | 55/3467 | 188/18723 | 2.16e-04 | 3.01e-03 | 55 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa00330 | Colorectum | AD | Arginine and proline metabolism | 23/2092 | 50/8465 | 8.27e-04 | 5.90e-03 | 3.76e-03 | 23 |
| hsa01230 | Colorectum | AD | Biosynthesis of amino acids | 28/2092 | 75/8465 | 9.99e-03 | 3.89e-02 | 2.48e-02 | 28 |
| hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
| hsa003301 | Colorectum | AD | Arginine and proline metabolism | 23/2092 | 50/8465 | 8.27e-04 | 5.90e-03 | 3.76e-03 | 23 |
| hsa012301 | Colorectum | AD | Biosynthesis of amino acids | 28/2092 | 75/8465 | 9.99e-03 | 3.89e-02 | 2.48e-02 | 28 |
| hsa012004 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
| hsa003304 | Colorectum | MSS | Arginine and proline metabolism | 23/1875 | 50/8465 | 1.52e-04 | 1.24e-03 | 7.61e-04 | 23 |
| hsa012005 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
| hsa003305 | Colorectum | MSS | Arginine and proline metabolism | 23/1875 | 50/8465 | 1.52e-04 | 1.24e-03 | 7.61e-04 | 23 |
| hsa012006 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
| hsa003306 | Colorectum | FAP | Arginine and proline metabolism | 16/1404 | 50/8465 | 5.33e-03 | 2.10e-02 | 1.27e-02 | 16 |
| hsa012007 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
| hsa003307 | Colorectum | FAP | Arginine and proline metabolism | 16/1404 | 50/8465 | 5.33e-03 | 2.10e-02 | 1.27e-02 | 16 |
| hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
| hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
| hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
| hsa0123021 | Liver | HCC | Biosynthesis of amino acids | 53/4020 | 75/8465 | 3.79e-05 | 2.11e-04 | 1.18e-04 | 53 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GOT2 | SNV | Missense_Mutation | novel | c.1213G>C | p.Asp405His | p.D405H | P00505 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| GOT2 | insertion | Frame_Shift_Ins | novel | c.553_554insGGCTTAATTTGGCAATGTCTCAACAGAGAGTC | p.Lys185ArgfsTer56 | p.K185Rfs*56 | P00505 | protein_coding | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| GOT2 | SNV | Missense_Mutation | c.469C>G | p.Leu157Val | p.L157V | P00505 | protein_coding | tolerated(0.25) | benign(0.029) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GOT2 | SNV | Missense_Mutation | novel | c.104A>G | p.His35Arg | p.H35R | P00505 | protein_coding | tolerated(0.16) | benign(0) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| GOT2 | SNV | Missense_Mutation | rs754471368 | c.719N>T | p.Ala240Val | p.A240V | P00505 | protein_coding | tolerated(0.25) | benign(0.011) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| GOT2 | SNV | Missense_Mutation | c.986C>T | p.Ala329Val | p.A329V | P00505 | protein_coding | tolerated(0.08) | benign(0.005) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GOT2 | SNV | Missense_Mutation | novel | c.889G>A | p.Asp297Asn | p.D297N | P00505 | protein_coding | tolerated(0.13) | benign(0.018) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| GOT2 | SNV | Missense_Mutation | c.273T>A | p.Asn91Lys | p.N91K | P00505 | protein_coding | tolerated(0.82) | benign(0.007) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GOT2 | SNV | Missense_Mutation | novel | c.281N>G | p.Lys94Arg | p.K94R | P00505 | protein_coding | deleterious(0.03) | possibly_damaging(0.858) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| GOT2 | SNV | Missense_Mutation | novel | c.712N>A | p.Leu238Ile | p.L238I | P00505 | protein_coding | tolerated(0.25) | possibly_damaging(0.611) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |